Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Personalized predictive modeling for patients with Alzheimer's disease using an extension of Sullivan's life table model.

Stallard E, Kinosian B, Stern Y.

Alzheimers Res Ther. 2017 Sep 20;9(1):75. doi: 10.1186/s13195-017-0302-6.

2.

Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer's Disease: Transforming Functional Scores into Levels of Dependence.

Kahle-Wrobleski K, Andrews JS, Belger M, Gauthier S, Stern Y, Rentz DM, Galasko D.

J Prev Alzheimers Dis. 2015;2(2):115-120. doi: 10.14283/jpad.2015.53. Epub 2015 Jan 20.

3.

Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.

Michaud TL, High R, Charlton ME, Murman DL.

Alzheimer Dis Assoc Disord. 2017 Jul-Sep;31(3):209-217. doi: 10.1097/WAD.0000000000000198.

PMID:
28486240
4.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials.

Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, AlSafadi AM.

BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

5.

Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Change Observed.

Lacey L, Bobula J, Niecko T, Leibman C.

Neurol Ther. 2017 Jun;6(1):11-23. doi: 10.1007/s40120-016-0056-2. Epub 2016 Nov 22.

6.

The Predictors study: Development and baseline characteristics of the Predictors 3 cohort.

Stern Y, Gu Y, Cosentino S, Azar M, Lawless S, Tatarina O.

Alzheimers Dement. 2017 Jan;13(1):20-27. doi: 10.1016/j.jalz.2016.04.004. Epub 2016 May 21.

PMID:
27219818
7.

Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain.

Darbà J, Kaskens L.

Clinicoecon Outcomes Res. 2015 Jul 2;7:387-95. doi: 10.2147/CEOR.S81045. eCollection 2015.

8.

Subjective word-finding difficulty reduces engagement in social leisure activities in Alzheimer's disease.

Farrell MT, Zahodne LB, Stern Y, Dorrejo J, Yeung P, Cosentino S.

J Am Geriatr Soc. 2014 Jun;62(6):1056-63. doi: 10.1111/jgs.12850. Epub 2014 Jun 2.

9.

Social cognition in Alzheimer's disease: a separate construct contributing to dependence.

Cosentino S, Zahodne LB, Brandt J, Blacker D, Albert M, Dubois B, Stern Y.

Alzheimers Dement. 2014 Nov;10(6):818-26. doi: 10.1016/j.jalz.2013.12.021. Epub 2014 Mar 18.

10.

Health-care use and cost in dementia caregivers: Longitudinal results from the Predictors Caregiver Study.

Zhu CW, Scarmeas N, Ornstein K, Albert M, Brandt J, Blacker D, Sano M, Stern Y.

Alzheimers Dement. 2015 Apr;11(4):444-54. doi: 10.1016/j.jalz.2013.12.018. Epub 2014 Mar 15.

11.

Precipitating and predisposing events and symptoms for admission to assisted living or nursing home care.

Rockwood JKh, Richard M, Garden K, Hominick K, Mitnitski A, Rockwood K.

Can Geriatr J. 2013 Mar 5;17(1):16-21. doi: 10.5770/cgj.17.93. eCollection 2014 Mar.

12.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

13.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD.

JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. Erratum in: JAMA. 2014 Mar 19;311(11):1161.

14.

A new algorithm for predicting time to disease endpoints in Alzheimer's disease patients.

Razlighi QR, Stallard E, Brandt J, Blacker D, Albert M, Scarmeas N, Kinosian B, Yashin AI, Stern Y.

J Alzheimers Dis. 2014;38(3):661-8. doi: 10.3233/JAD-131142.

15.

Staging dementia from symptom profiles on a care partner website.

Rockwood K, Richard M, Leibman C, Mucha L, Mitnitski A.

J Med Internet Res. 2013 Aug 7;15(8):e145. doi: 10.2196/jmir.2461.

16.

Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression.

Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y.

Am J Geriatr Psychiatry. 2015 Feb;23(2):130-40. doi: 10.1016/j.jagp.2013.03.014. Epub 2013 Jul 17.

17.

Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.

Dysken MW, Guarino PD, Vertrees JE, Asthana S, Sano M, Llorente M, Pallaki M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Carney S, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Vatassery G.

Alzheimers Dement. 2014 Jan;10(1):36-44. doi: 10.1016/j.jalz.2013.01.014. Epub 2013 Apr 11.

18.

Validation of an informant-reported web-based data collection to assess dementia symptoms.

Rockwood K, Zeng A, Leibman C, Mucha L, Mitnitski A.

J Med Internet Res. 2012 Mar 12;14(2):e42. doi: 10.2196/jmir.1941.

19.

Costs of informal care for people suffering from dementia: evidence from a danish survey.

Jakobsen M, Poulsen PB, Reiche T, Nissen NP, Gundgaard J.

Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):418-28. doi: 10.1159/000333812. Epub 2011 Nov 18.

20.

Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease.

Frank L, Lenderking WR, Howard K, Cantillon M.

Alzheimers Res Ther. 2011 Dec 9;3(6):35. doi: 10.1186/alzrt97.

Supplemental Content

Support Center